title: Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era.
abstract: BACKGROUND
  There is at present no consensus on the policy for the treatment of patients with low-grade gliomas (LGGs).
  
  
  METHODS
  This report is a retrospective multi-institutional study of 100 patients (ages 16-65 years) with astrocytoma (grade II), oligodendroglioma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma of the supratentorial areas which were treated with surgery and postoperative radiotherapy at five university hospitals in northern Japan between 1990 and 1997 when MRI was routinely used to determine the target volume. Most patients were irradiated with 50-60 Gy. The target volume usually covered the areas with T2 prolongation of MRI with a margin of 2 cm.
  
  
  RESULTS
  The disease-specific 5-year survival rate was 87.4% for patients with oligodendroglioma and 75.3% for patients with astrocytoma. Survival for patients with astrocytoma in the MRI era appears to be improved compared with historical controls in the literature. Patients with astrocytoma aged 40 years and under had a significantly better disease-specific survival rate than those over 40 years (P < 0.05) and patients with oligodendroglioma and oligoastrocytoma showed a similar tendency. Patients with astrocytoma who had over 50% of their tumor removed had a significantly better survival rate than those who had less than 50% removed (P < 0.05). Chemotherapy appeared to improve the disease-specific survival rate of patients with oligodendroglioma but not that of patients with astrocytoma.
  
  
  CONCLUSIONS
  Oligodendroglioma has a more protracted course of disease progression than astrocytoma. This particular feature and the sensitivity of LGGs to chemotherapy as well as their relevant prognostic factors, such as age, histopathology and amount of tumor removal, should be taken into account before any decision on treatment methods for LGGs is made.
authors.affiliation: Department of Radiology, Sapporo Medical University, School of Medicine, Sapporo, Japan. sakatako@sapmed.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Sakata
authors.forename: M
authors.initials: M
authors.lastname: Hareyama
authors.forename: T
authors.initials: T
authors.lastname: Komae
authors.forename: H
authors.initials: H
authors.lastname: Shirato
authors.forename: O
authors.initials: O
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Watarai
authors.forename: K
authors.initials: K
authors.lastname: Takai
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: E
authors.initials: E
authors.lastname: Tsuchida
authors.forename: K
authors.initials: K
authors.lastname: Sakai
mesh_terms: D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015173:Supratentorial Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D015996:Survival Rate